作者: Thomas Buroker , P. N. Kim , Carl Groppe , Joseph McCracken , Robert O'Bryan
DOI: 10.1002/1097-0142(197910)44:4<1215::AID-CNCR2820440408>3.0.CO;2-S
关键词:
摘要: A randomized trial was conducted by the Southwest Oncology Group (SWOG) in advanced carcinoma of stomach and pancreas. Patients were assigned to receive monthly 5-fluorouracil 96-hour continuous infusions with either bolus mitomycin-C or oral methyl-CCNU. Mitomycin-C methyl-CCNU administered every eight weeks. The 5 FU-mitomycin combination produced a 14% 22% response rate disseminated pancreatic carcinoma, respectively. infusion FU achieved responses 9% 5% tumors, There ho significant difference survival between limbs for tumor. Median gastric on regimen 25 weeks vs. 18 FU-methyl-CCNU arm. In median mitomycin limb 19 as compared 17 program. Leukopenia greater first course limb. Regression analysis demonstrated that performance status most important pretreatment characteristic predicting both tumors. Neither appears significantly alter dismal prognosis upper gastrointestinal neoplasms.